131 related articles for article (PubMed ID: 14963065)
1. Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.
Gross M; Clements J; Beckett RP; Thomas W; Taylor S; Lofland D; Ramanathan-Girish S; Garcia M; Difuntorum S; Hoch U; Chen H; Johnson KW
J Antimicrob Chemother; 2004 Mar; 53(3):487-93. PubMed ID: 14963065
[TBL] [Abstract][Full Text] [Related]
2. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
Fritsche TR; Moet GJ; Jones RN
Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
Lofland D; Difuntorum S; Waller A; Clements JM; Weaver MK; Karlowsky JA; Johnson K
J Antimicrob Chemother; 2004 Apr; 53(4):664-8. PubMed ID: 14973152
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches to antimicrobial therapy: peptide deformylase.
Waller AS; Clements JM
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):785-92. PubMed ID: 12630299
[TBL] [Abstract][Full Text] [Related]
6. Streptococcus pneumoniae pneumonia in mice: optimal amoxicillin dosing predicted from a pharmacokinetic-pharmacodynamic model.
Moine P; Mazoit JX
J Pharmacol Exp Ther; 1999 Dec; 291(3):1086-92. PubMed ID: 10565828
[TBL] [Abstract][Full Text] [Related]
7. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
Girard D; Finegan SM; Dunne MW; Lame ME
J Antimicrob Chemother; 2005 Aug; 56(2):365-71. PubMed ID: 16002421
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Azoulay-Dupuis E; Mohler J; Bédos JP
Antimicrob Agents Chemother; 2004 Jan; 48(1):80-5. PubMed ID: 14693522
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones.
Fajdetić A; Vinter A; Paljetak HČ; Padovan J; Jakopović IP; Kapić S; Alihodžić S; Filić D; Modrić M; Košutić-Hulita N; Antolović R; Schoenfeld ZI; Mutak S; Eraković Haber V; Spaventi R
Eur J Med Chem; 2011 Aug; 46(8):3388-97. PubMed ID: 21600677
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains.
Treyaprasert W; Schmidt S; Rand KH; Suvanakoot U; Derendorf H
Int J Antimicrob Agents; 2007 Mar; 29(3):263-70. PubMed ID: 17194570
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.
Sun HK; Lee SY; Banevicius MA; Du X; Maglio D; Nicolau DP
J Antimicrob Chemother; 2005 Sep; 56(3):559-65. PubMed ID: 16024590
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
16. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin.
Koeth LM; Good CE; Saunders KA; Jakielaszek C
Int J Antimicrob Agents; 2004 Aug; 24(2):144-9. PubMed ID: 15288313
[TBL] [Abstract][Full Text] [Related]
17. Etest compared to broth microdilution: discrepant results when testing macrolides against Streptococcus pneumoniae indicate a need for better clinical and serum level/MIC correlation.
Sader H; Del'Alamo L
Braz J Infect Dis; 2000 Oct; 4(5):268-70. PubMed ID: 11063559
[No Abstract] [Full Text] [Related]
18. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
19. Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity.
Axten JM; Medina JR; Blackledge CW; Duquenne C; Grant SW; Bobko MA; Peng T; Miller WH; Pinckney T; Gallagher TF; Kulkarni S; Lewandowski T; Van Aller GS; Zonis R; Ward P; Campobasso N
Bioorg Med Chem Lett; 2012 Jun; 22(12):4028-32. PubMed ID: 22579486
[TBL] [Abstract][Full Text] [Related]
20. The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media.
Dagan R
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S127-30. PubMed ID: 17980558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
